Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Hokuyaku Takeyama Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was 円1,870 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hokuyaku Takeyama Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円2,777 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hokuyaku Takeyama Holdings EV-to-EBIT Related Terms
Hokuyaku Takeyama Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Hokuyaku Takeyama Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hokuyaku Takeyama Holdings EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Hokuyaku Takeyama Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Hokuyaku Takeyama Holdings's EV-to-EBIT falls into.
Hokuyaku Takeyama Holdings's current Enterprise Value is 円1,706 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hokuyaku Takeyama Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円2,777 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hokuyaku Takeyama Holdings (SSE:3055) has a EV-to-EBIT of 0.61 as of Sep. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hokuyaku Takeyama Holdings and its competitors. According to the industry distribution chart, Hokuyaku Takeyama Holdings ranks #2 out of 98 companies in the Medical Distribution industry, placing it in the top 2%.
Is Hokuyaku Takeyama Holdings' EV-to-EBIT too high?
Hokuyaku Takeyama Holdings' current EV-to-EBIT is 0.61. The Medical Distribution industry median EV-to-EBIT is 11.19. Hokuyaku Takeyama Holdings' value of 0.61 is 94.5% below this industry median. Based on the distribution chart, Hokuyaku Takeyama Holdings ranks #2 out of 98 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Hokuyaku Takeyama Holdings has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hokuyaku Takeyama Holdings' EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Hokuyaku Takeyama Holdings ranks #2 out of 98 companies for EV-to-EBIT. This places Hokuyaku Takeyama Holdings in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 11.19. Hokuyaku Takeyama Holdings' value of 0.61 is 94.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.19, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hokuyaku Takeyama Holdings's current EV-to-EBIT of 0.61 is 94.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hokuyaku Takeyama Holdings and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hokuyaku Takeyama Holdings's current EV-to-EBIT is 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hokuyaku Takeyama Holdings stock overvalued right now?
Based on GuruFocus' analysis, Hokuyaku Takeyama Holdings (SSE:3055) is currently considered Fairly Valued. The stock's GF Value™ is 円966.46, compared to a current price of 円913.00 — trading 5.5% below its estimated fair value. The current EV-to-EBIT is 0.61 and 94.5% below the Medical Distribution industry median of 11.19. Hokuyaku Takeyama Holdings' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Hokuyaku Takeyama Holdings (SSE:3055), the current EV-to-EBIT is 0.61 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hokuyaku Takeyama Holdings (SSE:3055) Overvalued in 2026?
Based on GuruFocus' analysis, Hokuyaku Takeyama Holdings stock appears to be undervalued.
The current stock price of 円913.00 is trading 5.5% below its estimated GF Value™ of 円966.46.
GuruFocus considers Hokuyaku Takeyama Holdings to be Fairly Valued.
Key valuation signals for SSE:3055:
EV-to-EBIT: 0.61
GF Value™: 円966.46 vs. price of 円913.00 (5.5% below fair value)
Industry Position: 94.5% below the Medical Distribution median (#2 of 98)
No single metric tells the full story. See the SSE:3055 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hokuyaku Takeyama Holdings Inc is a medical device wholesaler. The company also distributes ethical drugs and general-purpose medicines. It offers repair services for medical instruments and manages real estate for physics and chemistry instruments.
59GF Score
Get the complete analysis for SSE:3055
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SSE:3055 has been successfully added to your 
